清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Case report: A case of primary renal osteosarcoma

医学 肾切除术 腹痛 骨肉瘤 肠系膜 外科 转移 肾癌 外科肿瘤学 癌症 放射科 病变 病理 内科学
作者
Wei Su,Hao Fu,Xiangming Mao
出处
期刊:Medicine [Wolters Kluwer]
卷期号:103 (30): e39024-e39024 被引量:1
标识
DOI:10.1097/md.0000000000039024
摘要

Rationale: Primary renal osteosarcoma is an exceedingly rare malignant tumor. Fewer than 30 cases have been reported in the literature since 1936. Furthermore, it has a high risk of metastasis and a poor overall prognosis rate. Patient’s concerns: In this report, we present a case of osteosarcoma originating from the left kidney (21 cm × 18 cm × 11 cm) with adhesions of the descending colon mesentery and the abdominal wall. A 63-year-old male patient presented with flank pain and gross hematuria. Diagnoses: A computed tomography scan revealed that the lesion with irregular margins was observed at the lower pole of the left kidney. Enhanced CT scan showed significant inhomogeneous enhancement of the lesion, with non-enhancing necrotic areas. A radical nephrectomy was performed. The immunohistochemistry results support the diagnosis of osteosarcoma. Interventions: Postoperatively, the patient participated in clinical trials and received treatment with a PD-1 antibody (2 weeks/once). Outcomes: At the one-year follow-up, the patient reported late-stage systemic cancer-related pain, necessitating daily pain relief medication. Unfortunately, the patient passed away 18 months after the surgery. Lessons: The case reported here is an exceedingly rare malignant osteosarcoma that originated from the kidney with the invasion of the descending colon mesentery and the abdominal wall. The patient received treatment with a PD-1 antibody (2 weeks/once). However, the patient passed away 18 months after the surgery. With the application of genetic testing technology and advancements in molecular biology, it was expected that specific targeted therapies for this condition would emerge in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852应助木木圆采纳,获得10
5秒前
止观发布了新的文献求助10
36秒前
43秒前
打打应助止观采纳,获得10
49秒前
BOB007发布了新的文献求助10
49秒前
NI完成签到 ,获得积分10
53秒前
火鸟完成签到,获得积分10
1分钟前
踏雪完成签到,获得积分10
1分钟前
1分钟前
星际舟完成签到,获得积分10
1分钟前
1分钟前
2分钟前
小二郎应助追寻的摩托采纳,获得30
2分钟前
2分钟前
Skywalk满天星完成签到,获得积分10
2分钟前
止观发布了新的文献求助10
2分钟前
科研通AI6应助科研通管家采纳,获得10
2分钟前
追寻的摩托完成签到,获得积分10
2分钟前
激动的似狮完成签到,获得积分10
2分钟前
止观完成签到,获得积分10
2分钟前
3分钟前
3分钟前
隐形曼青应助有魅力发卡采纳,获得10
3分钟前
666yj完成签到 ,获得积分10
3分钟前
4分钟前
4分钟前
4分钟前
lanxinge完成签到 ,获得积分10
4分钟前
尹汉通发布了新的文献求助10
4分钟前
4分钟前
尹汉通完成签到,获得积分10
4分钟前
害怕的恶天完成签到,获得积分10
4分钟前
4分钟前
大胆的鲂发布了新的文献求助30
4分钟前
知行合一完成签到 ,获得积分10
5分钟前
Hollen完成签到 ,获得积分10
5分钟前
大胆的鲂完成签到,获得积分10
5分钟前
老石完成签到 ,获得积分10
5分钟前
6分钟前
6分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Hydrothermal Circulation and Seawater Chemistry: Links and Feedbacks 1200
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5149046
求助须知:如何正确求助?哪些是违规求助? 4345200
关于积分的说明 13530238
捐赠科研通 4187460
什么是DOI,文献DOI怎么找? 2296289
邀请新用户注册赠送积分活动 1296657
关于科研通互助平台的介绍 1240697